PEDMARK's commercial trajectory and 2033 generic exclusivity define whether Fennec can compound a niche pediatric otoprotection franchise into durable value

Fennec Pharmaceuticals is a commercial-stage company whose approved lead product, PEDMARK, protects children's hearing from damage caused by cisplatin chemotherapy used to treat solid tumors.

PEDMARK is an approved sodium thiosulfate product reducing cisplatin-induced ototoxicity in pediatric patients with localized solid tumors, generating $44.6M in FY2025 sales. The thesis resolves on whether PEDMARK sustains double-digit revenue growth long enough to justify the valuation before label or market saturation limits the addressable patient pool. The primary structural risk is off-label sodium thiosulfate compounding and investigator-initiated use outside Fennec's commercial channel eroding pricing discipline.